Pay in 4 interest-free payments of $5.95 Learn more
Ships within 48 hours · Estimated delivery Aug 25 - Aug 30
In a 48-week phase 2 study, there was a weight reduction of up to 24.2% in participants who received the medication
SURMOUNT-1: The Landmark Weight-Loss Trial The SURMOUNT-1 trial (N=2,539) enrolled adults with obesity (BMI 30) or overweight (BMI 27) with at least one weight-related comorbidity, excluding people with type 2 diabetes
Lower-dose therapy did not fully match continued high-dose therapy, but it preserved a large amount of the benefit
Ozempic, approved by the FDA in 2017, has been particularly beneficial in managing type 2 diabetes, helping in the reduction of HbA1c levels a critical indicator of long-term blood sugar control
Tirzepatide (Mounjaro, Zepbound) , another medication, falls under a class of drugs called GIP/GLP-1 dual receptor agonists
